What's in Kuhnil Pharmaceutical Co., Ltd.'s pipeline?

Kuhnil Pharmaceutical Co., Ltd. has 7 drugs in our index: 1 marketed, 0 filed, 6 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Kuhnil Pharmaceutical Co., Ltd.'s portfolio?

Top competitors by shared drug class: Daewoong Pharmaceutical Co. LTD., Kowa Research Institute, Inc., Beijing Tiantan Hospital, Chong Kun Dang Pharmaceutical, Hanmi Pharmaceutical Company Limited.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/kuhnil-pharmaceutical-co-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Kuhnil Pharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Kuhnil Pharmaceutical Co., Ltd. pipeline: 1 marketed, 0 filed, 6 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 6 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Pravastatin, Simvastatin, Atorvastatin, Rosuvastatin	Pravastatin, Simvastatin, Atorvastatin, Rosuvastatin	marketed	HMG-CoA reductase inhibitor (statin)	HMG-CoA reductase	Cardiovascular
KI1107 4 Capsules, QD	KI1107 4 Capsules, QD	phase 3	SGLT2 inhibitor	SGLT2	Diabetes
KI1001	KI1001	phase 3	Cell therapy / Regenerative medicine		Ophthalmology
Omega-3 fatty acid ethylester90	Omega-3 fatty acid ethylester90	phase 3	Omega-3 fatty acid derivative	PPAR, GPR120	Cardiovascular
KI1106 4g, QD	KI1106 4g, QD	phase 3	CD47/SIRPα inhibitor	CD47/SIRPα axis	Oncology
Atorvastatin Calcium 20mg, QD	Atorvastatin Calcium 20mg, QD	phase 3	HMG-CoA reductase inhibitor (statin)	HMG-CoA reductase	Cardiovascular
Rosuvastatin Calcium 20 MG, QD	Rosuvastatin Calcium 20 MG, QD	phase 3	HMG-CoA reductase inhibitor (statin)	HMG-CoA reductase	Cardiovascular

Therapeutic area mix

Cardiovascular · 4
Diabetes · 1
Oncology · 1
Ophthalmology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Daewoong Pharmaceutical Co. LTD. · 2 shared drug classes
Kowa Research Institute, Inc. · 2 shared drug classes
Beijing Tiantan Hospital · 2 shared drug classes
Chong Kun Dang Pharmaceutical · 2 shared drug classes
Hanmi Pharmaceutical Company Limited · 2 shared drug classes
JW Pharmaceutical · 2 shared drug classes
AstraZeneca · 2 shared drug classes
Merck Sharp & Dohme LLC · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Kuhnil Pharmaceutical Co., Ltd.:

Cite this brief

Drug Landscape (2026). Kuhnil Pharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/kuhnil-pharmaceutical-co-ltd. Accessed 2026-05-17.